For many other cases, an initial telehealth visit can help triage urgency
This can take anywhere from a few days to a few weeks, depending on the side effects and the individual
a direct causal link in humans has not been established, and current EU and UK summaries of product characteristics (SmPCs) for approved GLP-1-based therapies do not list this as a formal contraindication, though it remains a theoretical concern warranting caution People with severe gastrointestinal conditions , such as gastroparesis or inflammatory bowel disease Those with a history of pancreatitis , which has been associated with GLP-1 receptor agonist use Children and young people under 18 , who have not been studied in retatrutide trials to date People with a history of gallbladder disease or gallstones , given the known association between this drug class and gallbladder events Those with proliferative diabetic retinopathy or macular oedema , where rapid improvements in blood glucose control may carry additional risks People with severe renal or hepatic impairment , pending further safety data Age-related eligibility, renal function, hepatic status, and existing medications would all need to be carefully assessed by a qualified clinician before any treatment decision could be made
Nausea starts earliest, at days one to three after injection, peaks in weeks one to two, and often resolves by weeks four to eight
Combined results from the SUSTAIN 6 and PIONEER 6 trials showed a 24% reduction in heart attack, stroke, and heart-related deaths
Weeks 1016: The Compounding Phase This is where visible changes accelerate even as the scale slows down
